Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). by Brandt, SD et al.
For Peer Review
 
 
 
 
 
 
Return of the lysergamides. Part I: Analytical and 
behavioral characterization of 1-propionyl-d-lysergic acid 
diethylamide (1P-LSD) 
 
 
Journal: Drug Testing and Analysis 
Manuscript ID: DTA-15-0251.R1 
Wiley - Manuscript type: Research Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Brandt, Simon; School of Pharmacy & Biomolecular Sciences , Liverpool 
John Moores University 
Kavanagh, Pierce; Trinity Centre for Health Sciences, Department of 
Pharmacology and Therapeutics 
Westphal, Folker; State Bureau of Criminal Investigation Schleswig-
Holstein, Section Narcotics/Toxicology 
Stratford, Alexander; Synex Ltd,  
Elliott, Simon; ROAR Forensics,  
Hoang, Khoa; University of the Sciences, Department of Chemistry and 
Biochemistry 
Wallach, Jason; University of the Sciences, Department of Pharmaceutical 
Sciences 
Halberstadt, Adam; University of California San Diego, Department of 
Psychiatry 
Keywords: 
New psychoactive substances, LSD, psychedelics, 5-HT2A receptor, head-
twitch response 
Abstract: 
1-Propionyl-d-lysergic acid diethylamide hemitartrate (1P-LSD) has 
become available as a ‘research chemical’ in form of blotters and powdered 
material. This non-controlled derivative of d-lysergic acid diethylamide 
(LSD) has previously not been described in the published literature despite 
being closely related to 1-acetyl-LSD (ALD-52), which was developed in the 
1950s. This study describes the characterization of 1P-LSD in comparison 
with LSD using various chromatographic, mass spectrometric methods and 
nuclear magnetic resonance spectroscopy. An important feature common 
to LSD and other serotonergic hallucinogens is that they produce 5-HT2A-
receptor activation and induce the head-twitch response (HTR) in rats and 
mice. In order to assess whether 1P-LSD displays LSD-like properties and 
activates the 5-HT2A receptor, male C57BL/6J mice were injected with 
vehicle (saline) or 1P-LSD (0.025‒0.8 mg/kg, IP) and HTR assessed for 30 
min using magnetometer coil recordings. It was found that 1P-LSD 
produced a dose-dependent increase in HTR counts, and that it had ~38% 
(ED50 = 349.6 nmol/kg) of the potency of LSD (ED50 = 132.8 nmol/kg). 
Furthermore, the HTR was abolished when 1P-LSD administration followed 
pre-treatment with the selective 5-HT2A receptor antagonist M100907 (0.1 
mg/kg, SC), which confirms that the behavioral response is mediated by 
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
For Peer Review
activation of the 5-HT2A receptor. These results indicate that 1P-LSD 
produces LSD-like effects in mice, consistent with its classification as a 
serotonergic hallucinogen. Nevertheless, the extent to which 1P-LSD might 
show psychoactive effects in humans similar to LSD remains to be 
investigated.  
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Abstract 
 
1-Propionyl-d-lysergic acid diethylamide hemitartrate (1P-LSD) has become available 
as a ‘research chemical’ in form of blotters and powdered material. This non-
controlled derivative of d-lysergic acid diethylamide (LSD) has previously not been 
described in the published literature despite being closely related to 1-acetyl-LSD 
(ALD-52), which was developed in the 1950s. This study describes the 
characterization of 1P-LSD in comparison with LSD using various chromatographic, 
mass spectrometric methods and nuclear magnetic resonance spectroscopy. An 
important feature common to LSD and other serotonergic hallucinogens is that they 
produce 5-HT2A-receptor activation and induce the head-twitch response (HTR) in 
rats and mice. In order to assess whether 1P-LSD displays LSD-like properties and 
activates the 5-HT2A receptor, male C57BL/6J mice were injected with vehicle (saline) 
or 1P-LSD (0.025‒0.8 mg/kg, IP) and HTR assessed for 30 min using magnetometer 
coil recordings. It was found that 1P-LSD produced a dose-dependent increase in 
HTR counts, and that it had ~38% (ED50 = 349.6 nmol/kg) of the potency of LSD 
(ED50 = 132.8 nmol/kg). Furthermore, the HTR was abolished when 1P-LSD 
administration followed pre-treatment with the selective 5-HT2A receptor antagonist 
M100907 (0.1 mg/kg, SC), which confirms that the behavioral response is mediated 
by activation of the 5-HT2A receptor. These results indicate that 1P-LSD produces 
LSD-like effects in mice, consistent with its classification as a serotonergic 
hallucinogen. Nevertheless, the extent to which 1P-LSD might show psychoactive 
effects in humans similar to LSD remains to be investigated.  
 
Introduction 
 
It is perhaps fair to consider that the synthesis[1] and discovery of the psychoactive 
properties of d-lysergic acid diethylamide (LSD)[2] (Figure 1) in 1943 triggered an 
avalanche of investigations that continue to capture the imagination of researchers 
across all disciplines.[3-10] Although the pharmacology and properties of LSD have 
been investigated in many studies, major questions still remain unanswered and are 
expected to occupy the attention of researchers in the future.[11-16]  
 
Reports have been published indicating LSD may possess therapeutic efficacy in 
patients suffering from disorders such as anxiety, alcoholism, cluster headaches, and 
autism, but unfortunately most of this evidence is anecdotal in nature or confounded 
by methodological shortcomings.[17-19] Importantly, although most clinical work with 
LSD ceased in the late 1960s, human trials have cautiously resumed during the last 
few years.[20-23] 
 
A range of lysergamide derivatives have been prepared to explore their molecular 
pharmacology (e.g.[24-32]) but the extent to which these show psychoactive properties 
in humans is not always clear.[7] In recent years, several lysergamide derivatives 
have been distributed as new psychoactive substances or “research chemicals” in 
the UK and Europe.[33] For example, lysergic acid 2,4-dimethylazetidide (LSZ)[31] and 
N6-allyl-6-norlysergic acid diethylamide (AL-LAD)
[24,30] are two lysergamide 
derivatives with LSD-like effects in animals that originated from academic research 
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and have been available for purchase in powdered and blotter form. Another closely 
related derivative with modification at the indole nitrogen is 1-acetyl-LSD (ALD-52) 
(Figure 1). Synthesis of ALD-52 was first reported in 1957 (e.g.[34]) and it was found 
to be psychoactive in humans[35-38] but it is not clear whether ALD-52 was also sold in 
the UK. Recent changes in UK legislation, however, precluded the open sale of 
several lysergamides, including ALD-52, LSZ and AL-LAD.[39] In response to those 
legal restrictions, 1-propionyl-LSD (Figure 1), also known as 1P-LSD, became 
available as a “research chemical” either as powdered material or on blotters. 
Although an assortment of LSD derivatives substituted at the 1-position have been 
described (e.g.[34,37,40-42]), it is noteworthy that chemical, analytical or pharmacological 
data related to 1-propionyl-LSD appear to be absent from the literature.  
 
Because of the difficulty associated with studying hallucinogens in humans, animal 
behavioral models are often used to investigate the pharmacology of hallucinogenic 
drugs. One behavioral model that has been widely adopted is the head twitch 
response (HTR), a paroxysmal side-to-side head movement induced by 5-HT2A 
agonists in rats and mice. The HTR is considered to be a rodent behavioral proxy for 
human hallucinogenic effects because it can distinguish between hallucinogenic and 
non-hallucinogenic 5-HT2A agonists.
[43-46] Although the HTR has traditionally been 
assessed using direct observation, new methods have been developed to detect the 
HTR in a semi-automated fashion using a head-mounted magnet and a 
magnetometer coil.[46,47] 
 
The present report details the analytical characterization of 1P-LSD using various 
chromatographic, mass spectrometric and spectroscopic methods relevant to clinical 
and forensic investigations. Supplementary analytical data derived from the 
characterization of LSD have also been included for comparative purposes. In 
addition, in vivo studies were conducted to assess the potential similarity between 
1P-LSD and LSD in regards to their 5-HT2A receptor pharmacology and behavioral 
effects. Previous investigations using magnetometer-based measurements have 
shown that LSD and other serotonergic hallucinogens induce the HTR in a dose-
dependent manner in male C57BL/6J mice[47] consistent with the mechanism of 5-
HT2A receptor activation involved in this behavior.
[45,47] In the present study, it was 
hypothesized that 1P-LSD would induce the HTR in mice if it had LSD-like 
properties. Furthermore, we predicted that pretreatment with a selective 5-HT2A 
receptor antagonist, such as M100907, would block the HTR induced by 1P-LSD, 
confirming the involvement of 5-HT2A receptor activation.       
 
Experimental 
 
Materials 
 
All chemicals used were of analytical and HPLC grade and obtained from Aldrich 
(Dorset, UK). d6-DMSO (99.8% D) was from VWR (Leicestershire, UK). 1-Propionyl-
d-lysergic acid diethylamide hemitartrate powder (1P-LSD) was supplied by Synex 
Ltd (London, UK), M100907 was from Hoechst Marion Roussel (Kansas City, MO, 
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USA), and LSD tartrate was from Ultrafine Chemicals (Manchester, UK). One blotter 
labelled to contain 100 µg 1P-LSD was purchased from an Internet vendor.   
 
Instrumentation 
 
Nuclear magnetic resonance spectroscopy  
 
NMR spectra were recorded in d6-DMSO using a Bruker Avance 300 spectrometer 
(1H at 300.1 MHz; 13C at 75 MHz) and suggested assignments were aided by 1-D 
and 2-D experiments. Internal chemical shift references were based on residual 
solvent peaks.  
 
Gas chromatography mass spectrometry 
 
Electron ionization (EI) mass spectra (70 eV) were obtained with a Finnigan TSQ 
7000 triple stage quadrupole mass spectrometer coupled to a gas chromatograph 
(Trace GC Ultra, Thermo Electron) using a CTC CombiPAL (CTC Analytics, 
Switzerland) autosampler.  The emission current was 200 µA and the scan time was 
1 s spanning a scan range between m/z 29 – m/z 600. The ion source temperature 
was maintained at 175 °C. Samples were introduced via gas chromatography with 
splitless injection using a fused silica capillary DB-1 column (30 m x 0.25 mm, film 
thickness 0.25 µm). The temperature program consisted of an initial temperature of 
80 °C, held for 1 min, followed by a ramp to 280 °C at 15 °C/min. The final 
temperature was held for 21 min. The injector temperature was 220 °C. The transfer 
line temperature was maintained at 280 °C and the carrier gas was helium in 
constant flow mode at a flow rate of 1.0 mL/min. Approximately 2 mg were dissolved 
in 1.5 mL methanol. For analysis, 1 µL sample solutions were injected into the GC-
MS system.  
 
High-resolution electrospray mass spectrometry  
The ultrahigh-performance liquid chromatography quadrupole time of flight single and 
tandem mass spectrometry (UHPLC-QTOF-MS/MS) conditions were used as 
described previously.[48,49] Mobile phases used for UHPLC separation consisted of 
100% acetonitrile (1% formic acid) and an aqueous solution of 1% formic acid. The 
column temperature was set at 40 °C (0.6 mL/min) and data were acquired for 5.5 
min. The elution was a 5–70% acetonitrile gradient ramp over 3.5 min, then 
increased to 95% acetonitrile in 1 min and held for 0.5 min before returning to 5% 
acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode scanning from 
m/z 100 – m/z 1000 with and without auto MS/MS fragmentation. Ionization was 
achieved with an Agilent JetStream electrospray source and infused internal 
reference masses. Agilent 6540 QTOF-MS parameters: gas temperature 325 °C, 
drying gas 10 L/min and sheath gas temperature 400 °C. Internal reference ions at 
m/z 121.05087 and m/z 922.00979 were used.   
 
Liquid chromatography electrospray mass spectrometry 
 
LC-MS analyses were performed on an Agilent 1100 system. Separation was 
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obtained on a Restek (Bellefonte, PA, USA) Allure PFPP column (5 µm, 50 x 2.1mm). 
Mobile phase A consisted of 0.1% formic acid in water, whereas, mobile phase B 
consisted of 0.1% formic acid in acetonitrile. The Agilent LC-MSD settings were as 
follows: positive electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 
L/min at 350 °C, nebulizer gas (N2) pressure 50 psi, Scan mode m/z 70 – 500, 
fragmentor voltage 150 V. The sample for LC-MS analysis was dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 10 µg/mL. 
The injection volume was 1 µL, flow rate was 0.80 mL/min and the column 
temperature was 30 °C. The total run time was 25 min. The following gradient elution 
program was used: 0–2 min 2% B, followed by an increase to 60% within 15 min, 
then up to 80% within 20 min, returning to 2% within 25 min. 
 
Gas chromatography solid-state infrared analysis 
 
The methanolic solution was measured on a GC-solid phase-IR-system consisting of 
an Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent G4567A 
and a DiscovIR-GC™ (Spectra Analysis, Marlborough, Massachusetts, USA). The 
column eluent was cryogenically accumulated on a rotating ZnSe disk that was 
cooled by liquid nitrogen. The IR spectra were directly recorded through the IR-
transparent ZnSe disk using a nitrogen cooled MCT detector. GC parameters: the 
injection was carried out in splitless mode with an injection port temperature of 
240 °C and a DB-1 fused silica capillary column (30 m x 0.32 mm i.d., 0.25 µm film 
thickness). The carrier gas was helium with a flow rate of 2.5 mL/min; oven 
temperature program: 80 °C for 2 min, ramped to 290 °C at 20 °C/min, and held at 
the final temperature for 25 min. The transfer line heater was set at 280 °C. IR 
conditions: oven temperature, restrictor temperature, disc temperature, and dewar 
cap temperatures were 280 °C, 280°C, −40 °C, and 35 °C, respectively. The vacuum 
was 0.2 mTorr, disc speed 3 mm/s, spiral separation was 1 mm, wavelength 
resolution 4 cm-1 and IR range 650–4000 cm-1. Acquisition time was 6s/file with 64 
scans/spectrum. Data were processed using GRAMS/AI Ver. 9.1 (Grams 
Spectroscopy Software Suite, Thermo Fischer Scientific) followed by implementation 
of the OMNIC Software, Ver. 7.4.127 (Thermo Electron Corporation). 
 
Animal pharmacology  
 
Male C57BL/6J mice (6−8 weeks old) were obtained from Jackson Laboratories (Bar 
Harbor, ME, USA) and housed up to four per cage with a reversed light-cycle (lights 
on at 1900 h, off at 0700 h). Food and water were provided ad libitum, except during 
behavioral testing. Testing was performed between 1000 and 1830 h. The head 
twitch response (HTR) was detected using a head mounted magnet and a 
magnetometer coil.[47] Mice received intraperitoneal (IP) vehicle (saline) or 1P-LSD 
(0.025, 0.05, 0.1, 0.2, 0.4, or 0.8 mg/kg), and then HTR was assessed for 30 min.   
For the antagonist study, mice received subcutaneous (SC) vehicle (water containing 
5% Tween-80) or 0.1 mg/kg M100907 20 min before IP vehicle (saline) or 0.4 mg/kg 
1P-LSD, and then HTR was assessed for 20 min. The injection volume was 5 mL/kg.  
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Analysis 
 
For the 1P-LSD dose-response study, HTR counts were analyzed using one-way  
ANOVAs, with time as a repeated measure (when appropriate); post-hoc 
comparisons were made using Tukey’s studentized range method. For the 
antagonist blockade study, HTR counts were analyzed using the Kruskal-Wallis test; 
post-hoc comparisons were made using the Dwass-Steel-Chritchlow-Fligner test.  
Significance was demonstrated by surpassing an α-level of 0.05. ED50 values and 
95% confidence limits were calculated using nonlinear regression. 
 
 
Results and discussion 
 
The ability to characterize and correctly identify new psychoactive substances 
constitutes an important part of forensic and clinical work. Aside from LSD, the 
analysis and analytical characterizations of lysergamide derivatives have been 
featured in investigations carried out in previous decades, possibly due to wider 
availability of LSD and greater interest at the time; examples include ALD-52, d-
lysergic acid N-methyl-N-propylamide (LAMPA) and a range of other N,N-dialkylated 
derivatives.[50-58] The analytical and pharmacological characterization of 1-propionyl-
d-lysergic acid diethylamide (1P-LSD) reported in the present study represents the 
newest addition to the field of lysergamide analysis within the filed of clinical study 
and the topic of new psychoactive substances that are available for purchase from 
Internet retailers.[33]  
 
Analytical features 
 
Gas chromatography electron ionization (EI) mass spectrometry (GC-MS) and 
retention time data for 1P-LSD and LSD are shown in Figure 2. A comparison of both 
EI mass spectra showed a number of common fragment ions with similar m/z values 
whereas others represented the corresponding mass shifts associated with the 
propionyl group in the 1-position. An example of this substituent-related shift may be 
seen in the fragment cluster at m/z 277, m/z 278 and m/z 279 (1P-LSD, Figure 2A) 
compared to the corresponding ions at m/z 221, m/z 222 and m/z 223 (LSD, Figure 
2B), respectively. A typical set of fragments observed in both mass spectra, for 
example, were represented by the cluster of ions at m/z 151 – m/z 154 which 
indicated that 1P-LSD might have shown some converging fragmentation behavior. 
Intense molecular ions were detected in both cases (1P-LSD at m/z 379; LSD at m/z 
323).  
 
A possible fragmentation pattern for 1P-LSD is suggested in Figure 3 and earlier 
literature on EI mass spectrometry of LSD was particularly helpful for comparison 
and mechanistic considerations.[50,55,56,59-61] Similar to what was observed with LSD, 
iminium ion formation at m/z 72 was thought to be associated with α-cleavage 
induced mechanisms depending on the site of ionization, i.e. either directly or via m/z 
100, respectively (Figure 3A).[58] Figures 3B1 – 3B4 depict a number of either radical 
cleavages or neutral losses to account for the detection of m/z 336, m/z 322, m/z 279 
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and m/z 252 (EI mass spectrum in Figure 2A), respectively. With the exception of 
m/z 322 (Figure 3B2), which represented the loss of the acyl radical from 1P-LSD, 
the remaining three species might have represented the propionyl substituted 
counterparts of those species previously described for LSD detected at m/z 280 
(retro-Diels Alder), m/z 223 and m/z 196 (loss of N,N-diethylacrylamide) (Figure 
2B).[50] Neutral loss of N,N-diethylformamide from the M
+
 might have led to the 
formation of the m/z 278 ion (Figures 2A and 3C), presumably in alignment with the 
m/z 222 counterpart observed in the EI mass spectrum of LSD (Figure 2B).[50] In 
comparison, the published EI mass spectrum of 1-acetyl LSD (ALD-52) revealed the 
detection of the retro-Diels Alder fragment at m/z 322 and the cluster of m/z 263, m/z 
264 and m/z 265 that signified the difference in mass compared to 1P-LSD. In 
addition to the M
+
 of ALD-52 at m/z 365, further key ions reported for ALD-52 
included m/z 249, m/z 238, the m/z 221 – m/z 223 cluster, m/z 207, m/z 181, m/z 
167, the m/z 151 – m/z 154 cluster, m/z 128 and m/z 100, respectively.[50] The 
remaining fragments and suggested mechanisms shown in Figures 3B4 and 3C 
exemplify a chain of radical and neutral losses frequently encountered during mass 
spectral analysis under EI conditions.[62] GC ion trap mass spectra of 1P-LSD 
recorded under EI chemical ionization conditions are provided as supplemental 
information. Under CI ion trap MS conditions, dissociation of the protonated molecule 
at m/z 380 gave rise to an abundant species at m/z 337, consistent with a neutral 
loss of N-methylmethanimine (supplemental data).  
 
The implementation of ultra high-performance liquid chromatography electrospray 
ionization accurate mass quadrupole time of flight tandem mass spectrometry 
(UHPLC-ESI-QTOF-MS/MS) for the detection of 1P-LSD and LSD is shown in Figure 
4. Separation between the two analytes was obtained leading to retention times of 
2.355 min for 1P-LSD (Figure 4A) and 2.029 min for LSD (Figure 4B), respectively. 
Furthermore, some of the mass spectral features were consistent with product ions 
specific for 1P-LSD due to additional mass units of 56 amu compared to LSD. 
Prominent examples included m/z 337 vs. m/z 281 and m/z 279 vs. m/z 223, 
respectively, and suggested structural representations and their possible 
mechanisms of formation are summarized in Figure 5. The main product ions 
observed for LSD under QTOF-MS/MS conditions essentially agreed with those 
reported previously using Fourier transform-ion cyclotron resonance mass 
spectrometry.[63] The presence of LSD in the 1P-LSD powdered product was not 
detected.  
 
As shown as supplemental data, analysis by diode array detection confirmed that 1P-
LSD and LSD gave distinct UV spectra that facilitated their differentiation. In the case 
of 1P-LSD, three absorption peaks were detected at 226 nm, 250 nm and 294 nm 
whereas two peaks were visible for LSD at 222 nm and 314 nm, respectively. The 
implementation of GC solid-state infrared analysis is shown in Figure 6. The eluting 
analyte was deposited cryogenically onto an IR-transparent zinc selenide disk that 
enabled the recording of the IR spectrum of the solidified eluent. Key features in the 
IR spectrum were reminiscent of those reported for ALD-52 where, for example, the 
absence of the N-H stretch was noted as a consequence of substitution at the indole 
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nitrogen. The appearance of two strong carbonyl bands at 1703.7 cm-1 (1-acetyl) and 
1637.5 cm-1 (amide carbonyl) were also consistent with the structure.[34,51]        
 
Determination of accurate mass values confirmed acceptable mass accuracy for the 
molecular formulae linked to the protonated molecules and possible product ions. 
Detected key product ions included m/z 337.19047 (C21H25N2O2
+) (Figure 5A1, loss 
of N-methylmethanimine) and m/z 279.14899 (C18H19N2O
+) that might be rationalized 
by a loss of N,N-diethylformamide (C5H11NO) from the protonated molecule 
(C23H30N3O2
+), see Figure 5A2. A product ion observed in both spectra was 
associated with C14H10NO
+ at m/z 208.07591 (1P-LSD) and m/z 208.07578 (LSD), 
respectively. A proposed mechanism of formation from 1P-LSD is provided in Figure 
5A3. In such a scenario, a precursor ion at m/z 264 (C17H14NO2
+; calculated m/z 
264.10191) would have been required in order to continue dissociation by loss of 
prop-1-en-1-one (C3H4O) to give the detected species at m/z 208.07591. An ion with 
very low abundance was detected at m/z 264.10460 under QTOF-MS/MS conditions 
although both accuracy (∆ + 10.19 ppm) and isotopic match were considered 
unsatisfactory. A potential reason for the difficulty encountered in ion detection might 
have reflected the preferred loss of CO as the driving force for its dissociation. 
Interestingly, a m/z 264 ion was detected cross platform when employing HPLC ESI 
single quadrupole mass spectrometry and in-source collision-induced dissociation 
(Figure 4C). A potential alternative for m/z 279.14899 might have involved the loss of 
N,N-diethylamine (C4H11N) from the protonated molecule to give m/z 307.14283 
(C19H19N2O2
+) followed cleavage of CO (Figure 5A4). As previously demonstrated 
with the detection of the new psychoactive substance 2-methoxydiphenidine (MXP) 
from a tablet surface,[64] the analysis of a 1P-LSD blotter by matrix-assisted ionization 
inlet Orbitrap mass spectrometry provided mass spectral information that agreed with 
those detected under QTOF-MS/MS conditions (supplemental data). An additional 
ESI triple quadrupole tandem mass spectrum was added as supplemental 
information that also showed comparable product ions.  
 
Analysis of 1P-LSD by nuclear magnetic resonance spectroscopy (NMR) was aided 
by implementation of 1-D and 2-D experiments including 1H/1H COSY, 1H/13C HSQC 
and 1H/13C HMBC. For comparison purposes, 1-D and 2-D spectra were also 
acquired for a LSD tartrate sample under identical conditions (d6-DMSO as solvent at 
300 / 75 MHz). Table 1 summarizes the suggested assignments and representative 
spectral data for 1P-LSD, i.e. HSQC and DEPTQ, are presented in Figure 7 for 
illustrative purposes. All remaining NMR data for 1P-LSD and LSD are supplied in 
form of supplemental information.  
 
The integration value measured for the tartrate singlet at 4.26 ppm was consistent 
with the presence of 1P-LSD hemitartrate and a molar ratio of 1:2 for tartaric acid:1P-
LSD (Table 1, Figure 7A). In comparison, 1H NMR analysis of a commercial sample 
of LSD tartrate showed the presence of a molar ratio of 1:1 for tartaric acid:LSD 
based on the integrals associated with the tartrate methine protons at 4.23 ppm 
(supplemental data). The NMR data obtained for 1P-LSD is consistent with its 
structure and closely related substances reported before.[52,65-69] In the proton NMR 
spectrum, the chemical shifts linked to the propionyl group overlapped with the 
resonances associated with one of the methyl groups of the N,N-diethylamide group, 
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H-7α and H-5β (Figure 7A), respectively. The singlet representing the N6-methyl 
group (H-17) was found to display the same chemical shift value as the solvent used 
for analysis (d6-DMSO), which also included an overlap with H-4α. Interestingly, the 
solvent overlap was not observed in the spectrum of the LSD tartrate sample 
although H-17 still showed an overlap with H-4α (supplemental data). Inspection of 
the 1H NMR spectrum also showed that one of the methylene groups belonging to 
the diethylamide group (H-20) (restricted rotation) appeared as a multiplet rather than 
the expected quartet as seen with the second set of H-20 at 3.45 ppm (Table 1, 
Figure 7A). At closer inspection, it was considered that this might have been 
consistent with two overlapping quartets of doublets (Table 1). Due to the adjacent 
chiral centre, one of the methylene groups may be considered prochiral. This 
resulted in geminal coupling and coupling to the adjacent methyl group, thus, 
resulting in the formation of a doublet of quartet for each proton of the methylene 
group. Interestingly, this was not observed in the 1H of the LSD tartrate sample 
where two quartets (overlapping with H-5β) were observed (supplemental data).  
 
The 13C NMR spectrum of LSD recorded in this study was in agreement with one 
report published in 1981 where the same solvent was used as well.[65] For 1P-LSD, 
the 13C chemical shift differences recorded for C-3 was particularly pronounced (LSD: 
108.06; 1P-LSD: 115.96) whereas the chemical shift values for the non-aromatic 
carbons were not affected by the presence of the propionyl group (Figure 7B and 
supplemental information). Interestingly, when Kidrič and Kocjan compared the 13C 
NMR spectrum of LSD with iso-LSD, one major shift difference was encountered with 
C-7 where the 55.8 ppm value (LSD) moved upfield to 50.7 ppm (iso-LSD).[65] 
Although the iso-1P-LSD epimer was not available in the present study, it appears 
tempting to consider the possibility of a similar epimeric upfield shift change for the 
8α-epimer. As typically observed with closely related LSD derivatives, the four 
protons linked to the two methylene groups at the 4- and 7-position can be observed 
as distinct resonances due to their axial and equatorial positions. The 1H/13C 
correlations observed in the HSQC experiment were helpful for the confirmation of 
assignments (Figure 7A). More detailed spectral representations, e.g. 1H, HSQC, 
COSY and HMBC data, may be obtained from the supplemental data collection. 
Following the approach taken by Bailey and Grey, who reported a conformational 
NMR study comparing d-lysergic acid dimethylamide (DAM-57[36]) and iso-lysergic 
acid dimethylamide, α- and β-assignments were made relative to the rigidly fixed 
position of the methine proton 5β-H that is placed above the ring plane of rings A and 
B (Table 1).[52]  
 
Head-twitch response 
 
To determine whether 1P-LSD produces LSD-like behavioral effects in vivo, we 
assessed whether it induced the HTR in mice.  Administration of 1P-LSD produced a 
dose-dependent increase in HTR counts (F(2,28)=13.16, p<0.0001; see Figure 8).  
1P-LSD stimulated the HTR with an ED50 of 158.9 (95% CI 65.0‒388.8) µg/kg.  
Based on molar mass, 1P-LSD (ED50 = 349.6 nmol/kg) has ~38% of the potency of 
LSD (ED50 = 132.8 nmol/kg
[47]). Extra sum-of-squares F tests showed the responses 
induced by LSD and 1P-LSD cannot be fit using a single regression model 
(F(4,47)=30.68, p<0.0001), and confirmed that 1P-LSD is significantly less potent 
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than LSD (F(1,47)=4.84, p<0.04).  As illustrated in Figure 9, the response to 1P-LSD 
is time-dependent (drug × time: F(30,140)=3.78, p<0.0001). The interval between 
drug treatment and peak behavioral response is inversely proportional to the dose of 
1P-LSD, with the maximal response occurring 15-20 min after administration of 0.2 
mg/kg, 10-20 min after 0.4 mg/kg, and 5-10 min after 0.8 mg/kg.  In summary, 1P-
LSD produced a LSD-like behavioral response in mice.   
 
In addition, a blockade experiment with the selective 5-HT2A antagonist M100907 
was carried out to confirm that 1P-LSD induces the HTR by activating the 5-HT2A 
receptor. M100907 has subnanomolar affinity for 5-HT2A and is at least 100-fold 
selective over 5-HT2B and 5-HT2C receptors.
[70,71] As anticipated, 0.4 mg/kg 1P-LSD 
did not induce the HTR in mice treated with 0.1 mg/kg M100907 (H(2)=13.01, 
p=0.001; Figure 10), demonstrating that the response to 1P-LSD is mediated by 5-
HT2A. 
 
The present findings show that there was a 3-fold reduction of potency in mice when 
the N1-hydrogen in LSD is replaced with a propionyl group.  Although 1P-LSD is less 
potent than LSD, it is still an extremely potent drug.  Indeed, for most hallucinogens, 
µmol/kg doses are required to induce behavioral responses in mice and rats.  For 
example, the HTR induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine 
(DOI) peaks at 4.47 µmol/kg in C57BL/6J mice.[72] 
 
Other N1-substituted lysergamides undergo extensive N1-dealkylation in vivo,
[73-75] 
and it is possible that 1P-LSD is hydrolyzed to LSD. Indeed, ALD-52 is equipotent 
with LSD[76] and is considered to serve as a pro-drug, although this does not seem to 
have ever been confirmed empirically. In order to gain initial insights into the potential 
for hydrolysis, 1P-LSD was exposed to incubation in human serum at 37 °C followed 
by LC-MS analysis in selective ion monitoring mode. As shown in the supplemental 
information, LSD detection was observed under a variety of exposure times. Follow-
up studies are currently being conducted to compare the affinity and selectivity of 
LSD and 1P-LSD at 5-HT receptors, and to determine whether 1P-LSD is hydrolyzed 
to LSD in vivo. 
 
Conclusion 
 
The present studies confirmed that 1P-LSD, a novel LSD derivative, is currently 
available as a ‘research chemical’.  To the best of the authors’ knowledge, 1P-LSD 
has never been described in the chemical literature and was an unknown compound 
prior to its appearance as a new psychoactive substance (NPS). The emergence of 
NPS pose challenges to researchers and health care professionals and the analytical 
characterization of 1P-LSD presented in this study provides key data that will be of 
interest to forensic investigators and clinicians. The fact that 1P-LSD was found to 
induce LSD-like behavioral effects in mice highlights the usefulness of a 
multidisciplinary approach to address the NPS phenomenon, which includes the 
need for further studies in this expanding field.  
 
 
Page 11 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 11
Acknowledgement 
 
The authors are grateful to Dr Sally Freeman (University of Manchester, UK) for 
helpful comments on NMR analysis. This work was supported by NIDA (R01 
DA002925) and NIMH (K01 MH100644). 
 
References 
 
[1] A. Stoll, A. Hofmann. Partialsynthese von Alkaloiden vom Typus des 
Ergobasins. 6. Mitteilung über Mutterkornalkaloide. Helv. Chim. Acta 1943, 26, 
944. 
[2] W.A. Stoll. Lysergsäure-diäthylamid, ein Phantastikum aus der 
Mutterkorngruppe. Schweiz. Arch. Neurol. Psychiat. 1947, 60, 279. 
[3] H.A. Abramson (Ed.), The Use of LSD in Psychotherapy and Alcoholism, 
Bobbs-Merrill Company, Inc., Indianapolis, IN, USA, 1967 
[4] S. Cohen, The beyond within: The LSD story, Second edition, Atheneum, 
New York, USA, 1967. 
[5] D.V. Siva Sankar, LSD - A Total Study, PJD Publications Ltd., Westbury, New 
York, USA, 1975. 
[6] A. Pletscher, D. Ladewig (Eds.), 50 Years of LSD: Current Status and 
Perspectives of Hallucinogens, The Panthenon Publishing Group, Inc., New 
York, 1994 
[7] A. Shulgin, A. Shulgin, TIHKAL: The Continuation, Transform Press, Berkeley, 
USA, 1997. 
[8] R.R. Laing (Ed.), Hallucinogens. A Forensic Drug Handbook, Elsevier 
Science Ltd., London, 2003 
[9] A. Hintzen, T. Passie, The Pharmacology of LSD. A Critical Review, Oxford 
University Press / Beckley Foundation Press, Oxford, 2010. 
[10] D.E. Smith, G.E. Raswyck, L.D. Davidson. From Hofmann to the Haight 
Ashbury, and into the future: the past and potential of lysergic acid 
diethlyamide. J. Psychoactive Drugs 2014, 46, 3. 
[11] D.E. Nichols. Hallucinogens. Pharmacol. Ther. 2004, 101, 131. 
[12] T. Passie, J.H. Halpern, D.O. Stichtenoth, H.M. Emrich, A. Hintzen. The 
pharmacology of lysergic acid diethylamide: a review. CNS Neurosci. Ther. 
2008, 14, 295. 
[13] F.X. Vollenweider, M. Kometer. The neurobiology of psychedelic drugs: 
implications for the treatment of mood disorders. Nat. Rev. Neurosci. 2010, 
11, 642. 
Page 12 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12
[14] A.L. Halberstadt, M.A. Geyer. Multiple receptors contribute to the behavioral 
effects of indoleamine hallucinogens. Neuropharmacology 2011, 61, 364. 
[15] A.L. Halberstadt, M.A. Geyer. Serotonergic hallucinogens as translational 
models relevant to schizophrenia. Int. J. Neuropsychopharmacol. 2013, 16, 
2165. 
[16] A.L. Halberstadt. Recent advances in the neuropsychopharmacology of 
serotonergic hallucinogens. Behav. Brain Res. 2015, 277, 99. 
[17] R.A. Sewell, J.H. Halpern, H.G. Pope, Jr. Response of cluster headache to 
psilocybin and LSD. Neurology 2006, 66, 1920. 
[18] J. Sigafoos, V.A. Green, C. Edrisinha, G.E. Lancioni. Flashback to the 1960s: 
LSD in the treatment of autism. Dev. Neurorehabil. 2007, 10, 75. 
[19] T.S. Krebs, P.O. Johansen. Lysergic acid diethylamide (LSD) for alcoholism: 
meta-analysis of randomized controlled trials. J. Psychopharmacol. 2012, 26, 
994. 
[20] P. Gasser, D. Holstein, Y. Michel, R. Doblin, B. Yazar-Klosinski, T. Passie, R. 
Brenneisen. Safety and efficacy of lysergic acid diethylamide-assisted 
psychotherapy for anxiety associated with life-threatening diseases. J. Nerv. 
Ment. Dis. 2014, 202, 513. 
[21] Y. Schmid, F. Enzler, P. Gasser, E. Grouzmann, K.H. Preller, F.X. 
Vollenweider, R. Brenneisen, F. Muller, S. Borgwardt, M.E. Liechti. Acute 
effects of lysergic acid diethylamide in healthy subjects. Biol. Psychiatry 2014,  
[22] P. Gasser, K. Kirchner, T. Passie. LSD-assisted psychotherapy for anxiety 
associated with a life-threatening disease: a qualitative study of acute and 
sustained subjective effects. J. Psychopharmacol. 2015, 29, 57. 
[23] R.L. Carhart-Harris, M. Kaelen, M.G. Whalley, M. Bolstridge, A. Feilding, D.J. 
Nutt. LSD enhances suggestibility in healthy volunteers. 
Psychopharmacology 2015, 232, 785. 
[24] A.J. Hoffman, D.E. Nichols. Synthesis and LSD-like discriminative stimulus 
properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide 
derivatives. J. Med. Chem. 1985, 28, 1252. 
[25] R. Oberlender, R.C. Pfaff, M.P. Johnson, X. Huang, D.E. Nichols. 
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-
aminobutane. J. Med. Chem. 1992, 35, 203. 
[26] X. Huang, D. Marona-Lewicka, R.C. Pfaff, D.E. Nichols. Drug discrimination 
and receptor binding studies of N-isopropyl lysergamide derivatives. 
Pharmacol. Biochem. Behav. 1994, 47, 667. 
Page 13 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 13
[27] R.C. Pfaff, X. Huang, D. Marona-Lewicka, R. Oberlender, D.E. Nichols, 
Lysergamides revisited. In Hallucinogens: An Update. NIDA Research 
Monograph 146, (Ed.: G.C. Lin, R.A. Glennon), National Institute on Drug 
Abuse, Rockville, MD, USA, 1994, pp. 52. 
[28] A.P. Monte, D. Marona-Lewicka, A. Kanthasamy, E. Sanders-Bush, D.E. 
Nichols. Stereoselective LSD-like activity in a series of d-lysergic acid amides 
of (R)- and (S)-2-aminoalkanes. J. Med. Chem. 1995, 38, 958. 
[29] D.E. Nichols, A. Monte, X. Huang, D. Marona-Lewicka. Stereoselective 
pharmacological effects of lysergic acid amides possessing chirality in the 
amide substituent. Behav. Brain Res. 1995, 73, 117. 
[30] V.J. Watts, C.P. Lawler, D.R. Fox, K.A. Neve, D.E. Nichols, R.B. Mailman. 
LSD and structural analogs: pharmacological evaluation at D1 dopamine 
receptors. Psychopharmacology 1995, 118, 401. 
[31] D.E. Nichols, S. Frescas, D. Marona-Lewicka, D.M. Kurrasch-Orbaugh. 
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation 
of the diethylamide moiety in the potent hallucinogenic agent N,N-
diethyllysergamide (LSD). J. Med. Chem. 2002, 45, 4344. 
[32] D.E. Nichols. Structure-activity relationships of serotonin 5-HT2A agonists. 
WIREs Membr. Transp. Signal. 2012, 1, 559. 
[33] S.D. Brandt, L.A. King, M. Evans-Brown. The new drug phenomenon. Drug 
Test. Anal. 2014, 6, 587. 
[34] F. Troxler, A. Hofmann. Substitutionen am Ringsystem der Lysergsäure I. 
Substitutionen am Indol-Stickstoff. 43. Mitteilung über Mutterkornalkaloide. 
Helv. Chim. Acta 1957, 40, 1706. 
[35] E. Rothlin. Lysergic acid diethylamide and related substances. Ann. N. Y. 
Acad. Sci. 1957, 66, 668. 
[36] H.A. Abramson. Lysergic acid diethylamide (LSD-25). XXIX. Response index 
as a measure of threshold activity of psychotropic drugs in man. J. Psychol. 
1959, 48, 65. 
[37] A. Hofmann, Die Mutterkornalkaloide: Vom Mutterkorn zum LSD - Die 
Chemie der Mutterkornalkaloide, Nachtschatten Verlag, Solothurn, 
Switzerland, 2000. 
[38] R.I. Katz, I.J. Kopin. Effect of d-LSD and related compounds on release of 
norepinephrine-H3 and serotonin-H3 evoked from brain slices by electrical 
stimulation. Pharmacol. Res. Commun. 1969, 1, 54. 
Page 14 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 14
[39] The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 No. 3271. 
Available at: http://www.legislation.gov.uk/uksi/2014/3271/made [21 July 
2015]. 
[40] F. Troxler, A. Hofmann. Substitutionen am Ringsystem der Lysergsäure II. 
Alkylierung. 44. Mitteilung über Mutterkornalkaloide. Helv. Chim. Acta 1957, 
40, 1721. 
[41] F. Troxler, A. Hofmann. Substitutionen am Ringsystem der Lysergsäure. III. 
Halogenierung. 45. Mitteilung über Mutterkornalkaloide. Helv. Chim. Acta 
1957, 40, 2160. 
[42] R.P. Pioch. Lysergic acid amides. Patent. US2997470. Eli Lilly and Company, 
Indianapolis, Ind, USA. 1961. 
[43] J. González-Maeso, N.V. Weisstaub, M. Zhou, P. Chan, L. Ivic, R. Ang, A. 
Lira, M. Bradley-Moore, Y. Ge, Q. Zhou, S.C. Sealfon, J.A. Gingrich. 
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling 
pathways to affect behavior. Neuron 2007, 53, 439. 
[44] J.B. Hanks, J. González-Maeso. Animal models of serotonergic psychedelics. 
ACS Chem. Neurosci. 2013, 4, 33. 
[45] C.E. Canal, D. Morgan. Head-twitch response in rodents induced by the 
hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a 
re-evaluation of mechanisms, and its utility as a model. Drug Test. Anal. 2012, 
4, 556. 
[46] A.L. Halberstadt, M.A. Geyer. Effects of the hallucinogen 2,5-dimethoxy-4-
iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head 
twitch response. Neuropharmacology 2014, 77, 200. 
[47] A.L. Halberstadt, M.A. Geyer. Characterization of the head-twitch response 
induced by hallucinogens in mice: detection of the behavior based on the 
dynamics of head movement. Psychopharmacology 2013, 227, 727. 
[48] S.P. Elliott, S.D. Brandt, S. Freeman, R.P. Archer. AMT (3-(2-
aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical 
challenge and implications for forensic analysis. Drug Test. Anal. 2013, 5, 
196. 
[49] Y.N. Soh, S. Elliott. An investigation of the stability of emerging new 
psychoactive substances. Drug Test. Anal. 2013, 6, 696. 
[50] S.W. Bellman. Mass spectral identification of some hallucinogenic drugs. J. 
Assoc. Off. Anal. Chem. 1968, 51, 164. 
[51] R.J. Mesley, W.H. Evans. Infrared identification of lysergide (LSD). J. Pharm. 
Pharmacol. 1969, 21, 713. 
Page 15 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 15
[52] K. Bailey, A.A. Grey. Conformational study of lysergic acid and isolysergic 
acid dialkylamides by proton magnetic resonance spectroscopy. Can. J. 
Chem. 1972, 50, 3876. 
[53] K. Bailey, D. Verner, D. Legault. Distinction of some dialkyl amides of lysergic 
and isolysergic acids from LSD. J. Ass. Off. Anal. Chem. 1973, 56, 88. 
[54] D.T. Stafford, H.S. Nichols, W.H. Anderson. Efficiency of capillary column gas 
chromatography in separating lysergic acid diethylamide (LSD) and lysergic 
acid methylpropylamide (LAMPA). J. Forensic Sci. 1984, 29, 291. 
[55] C.C. Clark. Differentiation of lysergic acid diethylamide (LSD) from N-methyl-
N-propyl and N-butyl amides of lysergic acid. J. Forensic Sci. 1989, 34, 532. 
[56] G.A. Neville, H.D. Beckstead, D.B. Black, B.A. Dawson, J.C. Ethier. USP 
Lysergic acid diethylamide tartrate (LOT 1) authentic substance 
recharacterized for authentication of a house supply of lysergide (LSD) 
tartrate. Can. J. Appl. Spectrosc. 1992, 37, 149. 
[57] J. Cai, J. Henion. Elucidation of LSD in vitro metabolism by liquid 
chromatography and capillary electrophoresis coupled with tandem mass 
spectrometry. J. Anal. Toxicol. 1996, 20, 27. 
[58] F. Westphal, T. Junge. Massenspektrometrische Unterscheidung von LSD, 
LAMPA und anderen LSD-Isobaren. Toxichem Krimtech 2014, 81, 129. 
[59] I.C. Nigam, J.L. Holmes. Mass spectrometry of lysergic acid diethylamide. J. 
Pharm. Sci. 1969, 58, 506. 
[60] Y. Nakahara, T. Niwaguchi. Lysergic acid diethylamide and related 
compounds. I. Synthesis of d-N6-demethyllysergic acid diethylamide. Chem. 
Pharm. Bull. 1971, 19, 2337. 
[61] C.C. Nelson, R.L. Foltz. Determination of lysergic acid diethylamide (LSD), 
iso-LSD, and N-demethyl-LSD in body fluids by gas chromatography/tandem 
mass spectrometry. Anal. Chem. 1992, 64, 1578. 
[62] F.W. McLafferty, F. Tureček, Interpretation of mass spectra, University 
Science Books, Sausalito, California, 1993. 
[63] W. Romão, B.D. Sabino, M.I. Bueno, B.G. Vaz, A.C. Júnior, A.O. Maldaner, 
E.V. de Castro, R.A. Lordeiro, C.C. Nascentes, M.N. Eberlin, R. Augusti. LSD 
and 9,10-dihydro-LSD analyses in street drug blotter samples via easy 
ambient sonic-spray ionization mass spectrometry (EASI-MS). J. Forensic Sci. 
2012, 57, 1307. 
[64] G. McLaughlin, N. Morris, P.V. Kavanagh, J.D. Power, J. O'Brien, B. Talbot, 
S.P. Elliott, J. Wallach, K. Hoang, H. Morris, S.D. Brandt. Test purchase, 
synthesis, and characterization of 2-methoxydiphenidine (MXP) and 
Page 16 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 16
differentiation from its meta- and para-substituted isomers. Drug Test. Anal. 
2015, in press: doi: 10.1002/dta.1800. 
[65] J. Kidrič, D. Kocjan. 13C NMR study of the conformation of some ergolene 
derivatives. Stud. Phys. Theor. Chem. 1982, 18, 53. 
[66] L. Pierri, I.H. Pitman, I.D. Rae, D.A. Winkler, P.R. Andrews. Conformational 
analysis of the ergot alkaloids ergotamine and ergotaminine. J. Med. Chem. 
1982, 25, 937. 
[67] A.F. Casy. Rapid identification of ergot derivatives by 1H-NMR spectroscopy. 
J. Pharm. Biomed. Anal. 1994, 12, 27. 
[68] N.J. Bach, H.E. Boaz, E.C. Kornfeld, C.-J. Chang, H.G. Floss, E.W. Hagaman, 
E. Wenkert. Carbon-13 nuclear magnetic resonance spectroscopy of naturally 
occurring substances. XXI. Nuclear magnetic resonance spectral analysis of 
the ergot alkaloids. J. Org. Chem. 1974, 39, 1272. 
[69] M.J. Vázquez, A.M. Roa, F. Reyes, A. Vega, A. Rivera-Sagredo, D.R. 
Thomas, E. Díez, J.A. Hueso-Rodríguez. A novel ergot alkaloid as a 5-HT1A 
inhibitor produced by Dicyma sp. J. Med. Chem. 2003, 46, 5117. 
[70] M.G. Palfreyman, C.J. Schmidt, S.M. Sorensen, M.W. Dudley, J.H. Kehne, P. 
Moser, M.W. Gittos, A.A. Carr. Electrophysiological, biochemical and 
behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic 
function. Psychopharmacology 1993, 112, S60. 
[71] J.H. Kehne, B.M. Baron, A.A. Carr, S.F. Chaney, J. Elands, D.J. Feldman, 
R.A. Frank, P.L. van Giersbergen, T.C. McCloskey, M.P. Johnson, D.R. 
McCarty, M. Poirot, Y. Senyah, B.W. Siegel, C. Widmaier. Preclinical 
characterization of the potential of the putative atypical antipsychotic MDL 
100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. 
Pharmacol. Exp. Ther. 1996, 277, 968. 
[72] C.E. Canal, U.B.O. da Silva, P.J. Gresch, E.E. Watt, E. Sanders-Bush, D.C. 
Airey. The serotonin 2C receptor potently modulates the head-twitch 
response in mice induced by a phenethylamine hallucinogen. 
Psychopharmacology 2010, 209, 163. 
[73] A. Enz, P. Donatsch, R. Nordmann. Dopaminergic properties of mesulergine 
(CU 32-085) and its metabolites. J. Neural Transm. 1984, 60, 225. 
[74] U. Bredberg, G.S. Eyjolfsdottir, L. Paalzow, P. Tfelt-Hansen, V. Tfelt-Hansen. 
Pharmacokinetics of methysergide and its metabolite methylergometrine in 
man. Eur. J. Clin. Pharmacol. 1986, 30, 75. 
[75] E. Müller-Schweinitzer, C. Tapparelli. Methylergometrine, an active 
metabolite of methysergide. Cephalalgia 1986, 6, 35. 
Page 17 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 17
[76] H. Isbell, E.J. Miner, C.R. Logan. Relationships of psychotomimetic to anti-
serotonin potencies of congeners of lysergic acid diethylamide (LSD-25). 
Psychopharmacologia 1959, 1, 20. 
 
  
Page 18 of 30
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 18
FIGURE CAPTIONS 
 
Figure 1. Chemical structures of lysergamides d-LSD, 1-d-acetyl-LSD (ALD-52) and 
1-propionyl-d-LSD (1P-LSD). 
 
Figure 2. Electron ionization quadrupole mass spectra. A: 1-Propionyl-d-LSD (1P-
LSD). B: LSD  
 
Figure 3. Suggested electron ionization mass spectrometry fragmentation patterns 
for 1-propionyl-d-LSD (1P-LSD). 
 
Figure 4. Comparison of electrospray ionization single and tandem mass spectra. A: 
quadrupole time of flight tandem mass spectrum (QTOF-MS/MS) of 1-propionyl-d-
LSD (1P-LSD). B: ESI-QTOF-MS/MS of LSD. C: in-source CID spectrum of 1P-LSD 
under single quadrupole mass spectrometry conditions.  
 
Figure 5. Suggested formation of product ions of 1-propionyl-d-LSD (1P-LSD) 
following analysis by UHPLC-ESI-QTOF-MS/MS.  
 
Figure 6. GC-solid state-IR spectrum of 1P-LSD. The retention time was recorded at 
32.61 min. 
 
Figure 7. 1-Propionyl-d-LSD (1P-LSD) hemitartrate spectra. A: Heteronuclear single 
quantum coherence spectroscopy (HSQC) analysis. B: Distorsionless enhancement 
by polarization transfer spectrum with retention of quaternary carbons (DEPTQ). 
 
Figure 8. Effect of 1-propionyl-d-LSD (1P-LSD) on the head twitch response. Data 
are presented as group means ± SEM for the entire 30-min test session. *p < 0.01, 
significant difference from vehicle control group (Tukey’s test). 
 
Figure 9.  Time-course of the head twitch response induced by 1-propionyl-d-LSD 
(1P-LSD). Data are presented as group means during 5-min time blocks.  *p < 0.01, 
significant difference from vehicle control group (Tukey’s test). 
 
Figure 10.  Effect of pretreatment with the selective 5-HT2A antagonist M100907 on 
the head twitch response induced by 1-propionyl-d-LSD (1P-LSD). Mice were 
pretreated with vehicle or 0.1 mg/kg M100907 and then treated with vehicle or 0.4 
mg/kg 1P-LSD.  Data are presented as group means ± SEM over the entire 20-min 
test session. *p < 0.01, significant difference between groups (Dwass-Steel-
Chritchlow-Fligner test). 
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Figure 1. Chemical structures of lysergamides d-LSD, 1-d-acetyl-LSD (ALD-52) and 1-propionyl-d-LSD (1P-
LSD).  
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Figure 2. Electron ionization quadrupole mass spectra. A: 1P-LSD. B: LSD  
266x355mm (300 x 300 DPI)  
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Figure 3. Suggested fragmentation patterns for 1P-LSD following analysis by electron ionization mass 
spectrometry.  
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Comparison of electrospray ionization single and tandem mass spectra. A: quadrupole time of flight tandem 
mass spectrum (QTOF-MS/MS) of 1-propionyl-d-LSD (1P-LSD). B: ESI-QTOF-MS/MS of LSD. C: in-source 
CID spectrum of 1P-LSD under single quadrupole mass spectrometry conditions.  
190x178mm (300 x 300 DPI)  
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Figure 5. Suggested formation of product ions following exposure of 1P-LSD to characterization by QTOF-
MS/MS.    
285x417mm (300 x 300 DPI)  
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Figure 6. GC-solid state-IR spectrum of 1P-LSD. The retention time was recorded at 32.61 min.  
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1-Propionyl-d-LSD (1P-LSD) hemitartrate spectra. A: Heteronuclear single quantum coherence spectroscopy 
(HSQC) analysis. B: Distorsionless enhancement by polarization transfer spectrum with retention of 
quaternary carbons (DEPTQ).  
286x395mm (300 x 300 DPI)  
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Effect of 1-propionyl-d-LSD (1P-LSD) on the head twitch response. Data are presented as group means ± 
SEM for the entire 30-min test session. *p < 0.01, significant difference from vehicle control group (Tukey’s 
test).  
129x128mm (600 x 600 DPI)  
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Time-course of the head twitch response induced by 1-propionyl-d-LSD (1P-LSD). Data are presented as 
group means during 5-min time blocks.  *p < 0.01, significant difference from vehicle control group (Tukey’s 
test).  
167x133mm (300 x 300 DPI)  
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Effect of pretreatment with the selective 5-HT2A antagonist M100907 on the head twitch response induced 
by 1-propionyl-d-LSD (1P-LSD). Mice were pretreated with vehicle or 0.1 mg/kg M100907 and then treated 
with vehicle or 0.4 mg/kg 1P-LSD.  Data are presented as group means ± SEM over the entire 20-min test 
session. *p < 0.01, significant difference between groups (Dwass-Steel-Chritchlow-Fligner test).  
127x118mm (600 x 600 DPI)  
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Table 1. 
1
H and 
13
C NMR data for 1P-LSD hemitartrate in d6-DMSO at 300 / 75 MHz 
 
No. 
13
C [δ / ppm] 
1
H [δ / ppm] 
1 – – 
2 119.89 7.58 (d, JH-2/H-4α = 1.5 Hz, 1H) 
3 115.96 – 
4 26.08 2.44 (m, 4α-H) 
a,b
 
 
3.50 (dd, JH-4β/H-4α = 15.3 Hz, JH-4β/H-5β = 5.7 Hz, 
1H, 4β-H) 
c
 
 
5 61.79 3.13 – 3.06 (m, 1H, H-5β) 
d
 
6 – – 
7 55.28 3.06 – 2.95 (m, 1H, H-7α) 
d
 
 
2.62 (J = 10.8 Hz, 1H, H-7β) 
e
 
8 38.86 3.98 – 3.77 (m, 1H, H-8α)  
9 121.79 6.35 (s, 1H) 
10 133.42 – 
11 127.74 – 
12 116.49 7.35 (d, JH-12/H-13 = 6.5 Hz, 1H)
 f
 
13 125.88 7.31 (t, J = 7.5 Hz, 1H)
 g
 
14 114.74 8.01 (d, JH-14/H-13 = 7.4 Hz, 1H) 
15 133.12 – 
16 127.50 – 
17 43.07 2.56 – 2.35 (m, 3H) 
a
 
18 170.34 – 
19 – – 
20 41.55 3.45 (q, JH-20/H-21 = 6.8 Hz, 2H)
 c
 
20 39.34 3.33 (1H, dq, Jgem 13.4 Hz, JHH 6.8Hz)
 h
 
3.30 (1H, dq, Jgem 13.4 Hz, JHH 6.7Hz)
 h
 
21 14.79 1.18 (t, JH-21/H-20 = 7.3 Hz, 3H) 
21 13.03 1.06 (t, JH-21/H-20 = 7.0 Hz, 3H) 
22 172.46 – 
23 – – 
24 28.18 3.06 – 2.95 (m, 2H) 
d
 
25 8.55 1.18 (JH-25/H-24, J = 7.3 Hz, 3H) 
TA 
j
 173.22 – 
TA
 j
 72.00 4.26 (s, 0.5 H) 
k
 
a 
Similar shift range for H-17 and DMSO and overlap with H-4α between 2.55 – 2.39 ppm.
 
 
b 
Indication of potential overlapping doublet of doublets for H-4α.
 
 
c 
Overlap of H-4β and H-20 between 3.56 – 3.39 ppm.
 
 
1
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d 
Similar shift range for H-5β, H-7α and H-24 between 3.13 – 2.95 ppm.  
 
e 
Apparent triplet instead of doublet of doublets possibly due to Jgem = JHH. 
 
f  
Indication of potential doublet of doublets (JH-12/H-14 = 0.8 Hz).  
 
g 
Apparent triplet instead of doublet of doublets possibly due to JH-13/H-14 = JH-13/H-12. 
 
h 
Two overlapping doublets of quartets. Alternatively, multiplet between 3.39 – 3.24 ppm for 
H-20 methylene protons.  
 
i 
H-21 and H25 are overlapping triplets that appear to impact on accurate determination of J 
values for coupling between H-20 and H-21.  
 
 
 
j 
TA: tartaric acid.
 
 
 
k
 Reflecting molar ratio 1:2 for TA:1P-LSD (hemitartrate salt). Relative to the aromatic protons 
or H-9, the measured integration value was equivalent to 1H. In case of the LSD tartrate 
sample (suppl. information), the corresponding tartaric acid singlet gave an integral of 2H. 
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